ATE474602T1 - Verfahren zur behandlung von hiv-infektion - Google Patents

Verfahren zur behandlung von hiv-infektion

Info

Publication number
ATE474602T1
ATE474602T1 AT05723932T AT05723932T ATE474602T1 AT E474602 T1 ATE474602 T1 AT E474602T1 AT 05723932 T AT05723932 T AT 05723932T AT 05723932 T AT05723932 T AT 05723932T AT E474602 T1 ATE474602 T1 AT E474602T1
Authority
AT
Austria
Prior art keywords
hiv infection
treating hiv
treating
infection
hiv
Prior art date
Application number
AT05723932T
Other languages
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE474602(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE474602T1 publication Critical patent/ATE474602T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05723932T 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion ATE474602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
ATE474602T1 true ATE474602T1 (de) 2010-08-15

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723932T ATE474602T1 (de) 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion

Country Status (30)

Country Link
US (1) US7776863B2 (de)
EP (1) EP1732604B1 (de)
JP (1) JP4847441B2 (de)
KR (1) KR101158140B1 (de)
CN (1) CN1956720B (de)
AR (1) AR048333A1 (de)
AT (1) ATE474602T1 (de)
AU (1) AU2005235116B2 (de)
BR (1) BRPI0509140A (de)
CA (1) CA2561146C (de)
CY (1) CY1111613T1 (de)
DE (1) DE602005022420D1 (de)
DK (1) DK1732604T3 (de)
ES (1) ES2347801T3 (de)
GE (1) GEP20104925B (de)
HR (1) HRP20100434T1 (de)
IL (1) IL178141A (de)
IN (1) IN2012DN06436A (de)
MY (1) MY144318A (de)
NO (1) NO337116B1 (de)
NZ (1) NZ549778A (de)
PE (1) PE20060148A1 (de)
PL (1) PL1732604T3 (de)
PT (1) PT1732604E (de)
RU (1) RU2367439C2 (de)
SI (1) SI1732604T1 (de)
TW (1) TWI347184B (de)
UA (1) UA88463C2 (de)
WO (1) WO2005102392A2 (de)
ZA (1) ZA200607959B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (de) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituierte indol- und azaindol-oxoacetylpiperazinamidderivate
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
SG191841A1 (en) 2011-01-31 2013-08-30 Bristol Myers Squibb Co Methods of making hiv attachment inhibitor prodrug compound and intermediates
EP2696937B1 (de) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamid-, amidoxim- und amidrazonderivate als hiv-bindungsinhibitoren
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281960T3 (es) * 1998-03-02 2007-10-01 The University Of North Carolina At Chapel Hill Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso.
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
BR0214842A (pt) * 2001-12-12 2005-01-11 Bristol Myers Squibb Co Inibidores de integrase hiv
BRPI0215050B8 (pt) * 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem

Also Published As

Publication number Publication date
JP4847441B2 (ja) 2011-12-28
ZA200607959B (en) 2008-06-25
KR101158140B1 (ko) 2012-06-19
WO2005102392A2 (en) 2005-11-03
RU2006137555A (ru) 2008-04-27
CY1111613T1 (el) 2015-10-07
PE20060148A1 (es) 2006-03-04
CN1956720A (zh) 2007-05-02
NO20064547L (no) 2006-10-06
GEP20104925B (en) 2010-03-25
ES2347801T3 (es) 2010-11-04
DE602005022420D1 (de) 2010-09-02
WO2005102392A3 (en) 2006-07-20
RU2367439C2 (ru) 2009-09-20
NZ549778A (en) 2010-09-30
TW200538117A (en) 2005-12-01
IL178141A (en) 2010-11-30
US20050215545A1 (en) 2005-09-29
AR048333A1 (es) 2006-04-19
CA2561146A1 (en) 2005-11-03
DK1732604T3 (da) 2010-11-15
AU2005235116A1 (en) 2005-11-03
JP2007530540A (ja) 2007-11-01
MY144318A (en) 2011-08-29
IN2012DN06436A (de) 2015-10-09
HRP20100434T1 (hr) 2010-09-30
SI1732604T1 (sl) 2010-10-29
PT1732604E (pt) 2010-09-24
US7776863B2 (en) 2010-08-17
KR20070011322A (ko) 2007-01-24
PL1732604T3 (pl) 2010-12-31
AU2005235116B2 (en) 2011-03-31
CN1956720B (zh) 2010-12-15
NO337116B1 (no) 2016-01-25
BRPI0509140A (pt) 2007-09-04
EP1732604B1 (de) 2010-07-21
IL178141A0 (en) 2006-12-31
EP1732604A2 (de) 2006-12-20
UA88463C2 (ru) 2009-10-26
TWI347184B (en) 2011-08-21
HK1096540A1 (en) 2007-06-01
CA2561146C (en) 2013-12-24

Similar Documents

Publication Publication Date Title
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
ATE465742T1 (de) Tlr7-liganden zur behandlung von hepatitis c
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
EP2054047A4 (de) Verfahren zur behandlung von akutem akustischem trauma
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
ATA17552001A (de) Verfahren zur behandlung säurehältiger abwässer
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
EP1635801A4 (de) Verfahren zur behandlung und prävention von herzarrhythmie
EP2037736A4 (de) Verfahren zur behandlung von zystennierenerkrankungen
ATA6612003A (de) Verfahren zur reinigung von abwässern
EP1948675A4 (de) Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
EP1786465A4 (de) Verfahren zur detektion und behandlung von autoimmunstörungen
DE112005002653A5 (de) Verfahren zur Konfiguration von Feldgeräten
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
DE502004008042D1 (de) Verfahren zum umformen von blechen
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732604

Country of ref document: EP